Glycominds
Molecular Diagnostics: Celiac & Bowel
Company Overview
Snapshot
Founded in January 1999, Glycominds operates with 11–50 employees. The company was acquired by Medivie Therapeutic in April 2014, expanding its product line.
Business overview
Glycominds International is an innovative diagnostics company focused on developing and commercializing gastrointestinal disease management tools and services. Its core technology involves GI dry serum testing, which enables physicians to identify patients with Celiac Disease and Inflammatory Bowel Diseases (Crohn's Disease and Ulcerative Colitis). This technology aims to provide early, non-invasive, accurate, and cost-effective diagnosis, predict higher risk for complicated Crohn's Disease, and monitor Anti-TNF therapy. The company operates within the Health Tech & Life Sciences sector, specifically in Digital Medical Diagnostics, serving the healthcare and medical devices industries, including laboratories, primarily in the United States.
Strategic signal
In February 2011, Glycominds successfully completed an Initial Public Offering (IPO) on the Tel Aviv Stock Exchange. This event signaled market validation for its diagnostic technologies and provided capital for further development and commercialization of its gastrointestinal disease management tools.
Log in to access full profile ›Company Intelligence Q&A
- What is Glycominds' primary focus?
- Glycominds develops and commercializes gastrointestinal disease management tools and services, specializing in molecular diagnostics for conditions like Celiac Disease and Inflammatory Bowel Diseases.
- When was Glycominds acquired?
- Glycominds was acquired by Medivie Therapeutic in April 2014, leading to the expansion of Medivie Therapeutic's product line.
- What was a significant financial milestone for Glycominds?
- In February 2011, Glycominds completed an Initial Public Offering (IPO) on the Tel Aviv Stock Exchange.
- What kind of diagnostic technology does Glycominds offer?
- Glycominds utilizes GI dry serum testing to help identify patients with Celiac Disease and Inflammatory Bowel Diseases, predict disease complications, and monitor Anti-TNF therapy.